CYP2C19 and metabolic dysfunction-associated steatotic liver disease: Because CYP2C19 was consistently downregulated across three disease severity phenotypes in our study, and due to its actionability in personalized therapy for CYP2C19 substrate drugs like clopidogrel, we conducted a meta-analysis using 16 studies that measured CYP2C19 expression in NAFLD.